Loading
A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked. This dossier gathers the 0 products (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute lymphoblastic leukaemia | >99% | Flow cytometry, median % CD7+ blasts in 49 diagnostic T-ALL samples (incl. 14 ETP-ALL); stable at relapse and during chemotherapy | T-ALL/T-LBL only (~15% of ALL); B-ALL is CD7-negative | doi.org |
| Acute myeloid leukaemia | 30% | Flow cytometry, CD7 on leukaemic blasts (approximately 30% of AML patients) | CD7+ AML carries a worse prognosis | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1/2 | Active | A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | - | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD7" OR ABSTRACT:"CD7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD7, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd7.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd7.json. Licence CC BY-NC 4.0.